Drug facts

Tirzepatide, anxiety and mood

Quick answer

Zepbound’s Medication Guide lists anxiety, irritability and mood changes as possible signs of low blood sugar. The side-effects table covers reactions recorded in the trials, a separate question. FDA asked Lilly to remove the earlier warning about suicidal behavior and ideation after its review did not find an increased risk.

What the label says about mood and low blood sugar1

The August 2026 Zepbound Medication Guide includes anxiety, irritability and mood changes in its list of low-blood-sugar symptoms. The risk of low blood sugar is higher when tirzepatide is used with insulin or an insulin secretagogue. This is a different warning from the earlier warning about suicidal behavior and ideation.

The warning that was removed2

The current Zepbound prescribing information lists the February 2026 removal of its warning on suicidal behavior and ideation. FDA requested the change after reviewing evidence for an increased risk across the drug class.3

4

Europe reached a similar conclusion earlier, and it is worth being precise about its scope. The PRAC concluded in April 2024 that the evidence did not support a causal association between suicidal and self-injurious thoughts and five named GLP-1 receptor agonists — dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide. Tirzepatide was not one of them. It was never part of that review, so nobody can honestly say the EMA cleared it.

What the trials actually measured5

A post hoc analysis of SURMOUNT-1, -2 and -3 pooled 4,056 participants and looked specifically at psychiatric safety, using a depression questionnaire and a structured suicidality rating scale. Depressive symptoms improved more on tirzepatide than on placebo. Suicidal ideation was reported in 0.6% of participants in both arms; non-fatal suicidal behavior in 0.1% on tirzepatide and none on placebo.

The participants had no known major psychopathology. The analysis measured depression and suicidality and does not answer whether tirzepatide causes or worsens a preexisting anxiety disorder.

What a compounded vial changes1

On the label — Mounjaro / Zepbound

Zepbound’s Medication Guide lists mood changes among possible signs of low blood sugar. FDA’s request to remove the suicidal behavior and ideation warning addressed a separate question.

In a compounded vial

Not established, and for an additional reason. A compounded preparation has no label of its own, so there is no warnings section to be silent and no FDA review standing behind that silence. The trials above studied the approved product at stated doses under supervision; they are not a measurement of a compounded vial. The two blanks look identical and are not the same thing.

Where to take this6

Tell your prescriber about your mental health history and any new mood changes. The pooled trial findings apply to the population studied, which excluded people with known major psychopathology.

If what you are actually noticing is exhaustion rather than mood, the label does document that: what it reports about fatigue. If you are weighing this against the approved product, the difference is set out in compounded versus Zepbound.

Sources

  1. FDA prescribing information and Medication Guide for ZEPBOUND (tirzepatide), revision 8/2026 DailyMed
  2. FDA prescribing information for ZEPBOUND (tirzepatide), Recent Major Changes table, revision 8/2026 DailyMed
  3. FDA Drug Safety Communication, 13 January 2026, updated 3 April 2026 — request to remove the suicidal behavior and ideation warning from GLP-1 receptor agonist labeling FDA
  4. European Medicines Agency, PRAC meeting highlights, 8–11 April 2024 Source
  5. Post hoc analysis of SURMOUNT-1, -2 and -3 (PMID 41537305, Obesity, 2026) PubMed
  6. Compounded Tirzepatide editorial policy and medical disclaimer — this section states our own position and makes no claim from the label Read it